Dedicated to primary cells<br /><span>Product and service development</span>
Dedicated to primary cells
Product and service development

Dedicated to the development of primary cell products and services

Learn More
Primary Cells, Pharmacological Efficacy Services, and Product Services<br /><span>One-Stop Expert in Upstream Cell Solutions</span>
Primary Cells, Pharmacological Efficacy Services, and Product Services
One-Stop Expert in Upstream Cell Solutions

Dedicated to the development of primary cell products and services

Learn More
Dedicated to primary cells<br /><span>Product and service development</span>
Dedicated to primary cells
Product and service development

Dedicated to the development of primary cell products and services

Learn More
scroll down

About Us

Dedicated to primary cells
Product and Service Development

Hycells Biotechnology Co., Ltd. is an innovative biotechnology company specializing in primary cells, related reagents, and technical services. With a long-standing commitment to the fields of cell and gene therapy (CGT) and large-molecule therapeutics, the team is dedicated to providing customers with end-to-end, one-stop solutions for primary cell products—covering research and development, manufacturing, sales, and technical support.

View more

Sample Service

Learn more +
Consult Now +

Technical Service Platform

Learn more +
Consult Now +

Product Center

Quality first, innovation oriented

View more
Cultivation Products

Cultivation Products

.

Culture products generally refer to various reagents, consumables and equipment used for in vitro culture, expansion and maintenance of cells, and are widely used in scientific research, drug development, vaccine production, cell therapy and other fields.

Obtain Solutions →
Testing Products

Testing Products

.

Hycells is committed to becoming a leading global one-stop supplier of primary cells, related reagents, and services.

Obtain Solutions →
Other Products And Instruments

Other Products And Instruments

.

Hycells is committed to becoming a leading global one-stop supplier of primary cells, related reagents, and services.

Obtain Solutions →

Cultivation Products

Cultivation Products

Testing Products

Testing Products

Other Products And Instruments

Other Products And Instruments

Our Advantages

Primary Cells, Pharmacological Efficacy Services, and Product Services
One-Stop Expert in Upstream Cell Solutions

View more

Quality

High-quality technical standards

Professional

Professional laboratory research team

Compliance

Clinical Sample Collection Compliance System

After-sales

A comprehensive after-sales service system

News Updates

Stay updated on He Yousheng’s latest news

Company News
Industry News
Laws and Regulations

Hycells HiMag™ Immune Cell Sorting Technology Platform | High Purity, High Viability, Versatile Applications—Redefining the Benchmark for Cell Sorting

2026-06-22

With the rapid advancement of cell and gene therapies, the industry is placing increasingly stringent demands on the performance, batch-to-batch consistency, and supply-chain reliability of cell-sorting reagents. At present, the domestic market for sorting magnetic beads remains dominated by imported brands, and their high cost of use and uncertain supply have become significant barriers to both research and industrialization in China.

G4S Antibodies Enable a New Breakthrough in CAR‑T Cell Function Research | Professor Huang He’s Team Publishes in Nature Cancer, Unveiling a Novel Mechanism Regulating Ferroptosis (IF: 28.5) Quality First, Innovation Driven

2026-06-22

Recently, Professor Huang He’s team at Zhejiang University published in the top oncology journal “…”. Nature Cancer 》published a research paper titled “Iron-mediated ferroptosis impairs CAR-T cell function and antitumor efficacy.” This study is the first to reveal that Serum iron overload By elucidating the key mechanisms by which ferroptosis induces functional exhaustion of CAR‑T cells, we have proposed a targeted approach. ACSL4 Alternatively, a novel strategy involves using the ferroptosis inhibitor Fer-1 to enhance CAR-T cell persistence and antitumor efficacy.

Hycells’s Selected PBMC Reconstruction Data Presentation (Part 2)

2026-06-22

HuPBMC model Due to its rapid establishment (3–4 weeks) and ease of use, it has been widely employed for in vivo efficacy evaluation in tumor immunotherapy. However, the conventional model suffers from a critical limitation: the randomness and uncertainty inherent in donor selection. The root of the problem lies not in the model itself, but in the “seed” cells—PBMCs—introduced into the system.

Hycells’s Selected PBMC Reconstruction Data Presentation (Part 1)

2026-06-22

The humanized PBMC-CDX model is an essential tool for in vivo efficacy evaluation of tumor immunotherapy agents. However, significant inter‑donor variability exists in the engraftment efficiency, T‑cell subset differentiation, and the risk of graft‑versus‑host disease (GVHD) among different PBMC donors, which directly impacts model stability and the experimental window.

A Fresh Start, A New Beginning | Hycells’s Brand Identity Fully Reimagined

2026-06-09

Every step forward is aimed at fulfilling our mission even more effectively.

Focused on peptide immunogenicity assessment, precisely empowering tumor neoantigens.

2026-06-02

In the field of cancer immunotherapy, tumor neoantigen–specific T-cell responses serve as a key metric for assessing peptide immunogenicity. Leveraging its well-established in vitro assay platform, Hycells Biotechnology offers end-to-end services—ranging from initial screening of peptide immunogenicity and antigen‑specific T-cell expansion to validation of tumor cell‑killing activity—thereby supporting the efficient and reliable discovery and validation of neoantigens.

Quickly access products and solutions

Currently, Heyousheng has established nearly 1,000 square meters of R&D laboratories and has officially obtained GB/T 19001-2016/ISO 9001:2015 quality management system certification. The company has also been recognized as a “Shanghai High-Tech Enterprise” and a “Shanghai Specialized, Sophisticated, Distinctive, and Innovative SME.” Heyousheng is committed to becoming a world-leading one-stop supplier of primary cells, associated reagents, and related services.

Contact us now
021-36696819